Integer Holdings Corporation (ITGR) Dividend History

Integer Holdings Corporation (ITGR) is a global medical device manufacturer that designs and produces specialized medical devices and components. The company focuses on critical, life-sustaining products used in various medical specialties such as neuromonitoring, cardiac rhythm management, vascular, and orthopedics. With a history rooted in innovative healthcare solutions, Integer serves medical device OEMs and healthcare providers worldwide.

5830 Granite Parkway., Suite 1150, Plano, TX, 75024
Phone: (214) 618-5243
Website: https://www.integer.net

Dividend History

Integer Holdings Corporation currently does not pay dividends

Company News

  • Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4

    Integer Holdings Corporation will participate in the 2025 Wells Fargo Healthcare Conference in Boston, with executive leadership presenting a fireside chat on September 4th at 3:00 p.m. ET.

    GlobeNewswire Inc.
    Featured Companies: WFC
  • Integer Posts 19 Percent EPS Gain in Q2

    Integer, a medical device contract manufacturer, reported strong Q2 2025 financial results with 11.4% revenue growth, beating analyst estimates. The company raised full-year profit guidance and showed robust performance in Cardio & Vascular product lines.

    The Motley Fool
  • Why Integer (ITGR) is a Top Value Stock for the Long-Term

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

    Zacks Investment Research
  • Integer Can Drive Consolidation Of Medical Device Outsourcing, Bullish Analyst Projects

    Truist Securities initiated coverage on Integer Holdings Corporation (NYSE:ITGR), noting the company as one of the largest med device outsource manufacturers and a unique SMID MedTech asset. The analyst notes Integer’s profitability and leveraged EPS growth prospects (1.5-2x that of revenue), which can sustain a high-teens 2023-2026 EPS CAGR. Integer has increasing exposure (through the OEM supply chain) to growth segments & emerging product cycles across the MedTech sector, Truist writes. Also, a durable inorganic (tuck-in) strategy can add at least 1-2%+ on top of a high-single-digit organic top-line, the analyst adds. Related: Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA. Truist initiates with a Buy rating and ...Full story available on Benzinga.com

    Benzinga

Related Companies

Page data last updated 09/06/2025 08:50:36 UTC